================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 20, 2003
TRANSGENOMIC, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30975
(State of Formation) (Commission File Number)
911789357
(IRS Employer Identification Number)
12325 Emmet Street
Omaha, NE 68164
(Address of principal executive offices) (Zip Code)
(402) 452-5400
(Registrants' telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
================================================================================
Item 5. Other Events and Regulation FD Disclosure.
On November 20, 2003, the Company issued a press release announcing it has
signed an agreement with Fisher Scientific, a leading global provider of
scientific research products and services, to distribute Optimase Polymerase,
Transgenomic's high fidelity, thermostable polymerase enzyme for PCR (polymerase
chain reaction) amplification of DNA. The Company is attaching the press release
as Exhibit 99.1 to this Current Report on Form 8-K.
Item 7. Financial Statements and Exhibits.
(c) Exhibits
99.1 Press Release, dated November 20, 2003, announcing Transgenomic has signed
an agreement with Fisher Scientific, a leading global provider of
scientific research products and services, to distribute Optimase
Polymerase, Transgenomic's high fidelity, thermostable polymerase enzyme
for PCR (polymerase chain reaction) amplification of DNA.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
TRANSGENOMIC, INC.
By /s/ Michael J. Draper
------------------------------------------
Michael J. Draper, Chief Financial Officer
November 20, 2003
3